No­vo Nordisk Foun­da­tion to launch $260M vac­cine ini­tia­tive in ear­ly 2024

The No­vo Nordisk Foun­da­tion, which op­er­ates in­de­pen­dent­ly from the phar­ma com­pa­ny, is pump­ing DKK 1.8 bil­lion ($260 mil­lion) to launch an ini­tia­tive de­signed to de­vel­op res­pi­ra­to­ry dis­ease vac­cines.

The No­vo Nordisk Foun­da­tion Ini­tia­tive for Vac­cines and Im­mu­ni­ty (NIVI) will be­gin in the first quar­ter of next year and will hire up to 200 peo­ple.

The ini­tia­tive will bridge the gap be­tween aca­d­e­m­ic re­search and in­dus­try, “so it’s the best of both worlds,” said the Foun­da­tion’s SVP of in­fec­tious dis­ease Pe­ter An­der­sen.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER